bioRxiv Science⌕ Search

Biology subjects

Groha, S.

Publications and source records attributed to Groha, S..

3 recordsLinked to original sources

Discovery of disease-associated cellular states using ResidPCA in single-cell RNA and ATAC sequencing data

To enhance understanding of cellular heterogeneity and disease from single-cell sequencing data, we introduce ResidPCA, a robust method for cell state identification that models cell type heterogeneity. Simulations demonstrate ResidPCAs efficacy, particularly in complex scenarios, with its accuracy more than four times higher than conventional Principal Component Analysis (PCA) and over three times higher than Non-negative Matrix Factorization (NMF)-based methods in identifying states expressed across multiple cell types. In scRNA-seq data from light-stimulated mouse visual cortex cells, ResidPCA captures stimulus-driven variability with an accuracy more than five times higher than NMF methods. In single nucleus data from an Alzheimers disease cohort, ResidPCA identified 44 snATAC-based and 42 snRNA-based states. 30 snATAC states were significantly enriched for Alzheimers disease heritability and were often more significantly enriched than established cell types such as microglia. The ResidPCA-based snATAC state most significantly enriched for Alzheimers disease heritability further elucidates a recently identified mechanism involving the neuron-ODC-microglial axis. This state links early amyloid production in neurons and oligodendrocytes with later-stage microglial activation and immune response, driving Alzheimers disease progression. These results demonstrate ResidPCAs ability to reveal additional biological variation in single-cell data and uncover disease-relevant cell states.

genomics↗

Seeing beyond the target: Leveraging off-target reads in targeted clinical tumor sequencing to identify prognostic biomarkers

Clinical tumor sequencing is rapidly becoming a standard component of clinical care, providing essential information for selecting amongst treatment options and providing prognostic value. Here we develop a robust and scalable software platform (SBT: Seeing Beyond the Target) that mines discarded components of clinical sequences to produce estimates of a rich set of omics features including rDNA and mtDNA copy number, microbial species abundance, and T and B cell receptor sequences. We validate the accuracy of SBT via comparison to multimodal data from the TCGA and apply SBT to a tumor panel cohort of 2,920 lung adenocarcinomas to identify associations of clinical value. We replicated known associations of somatic events in TP53 with changes in rDNA (p=0.012); as well as diversity of BCR and TCR repertoires with the biopsy site (p=2.5x10-6, p<10-20). We observed striking differences in EGFR mutant lung cancers versus wild-type, including higher rDNA copy number and lower immune repertoire diversity. Integrating clinical outcomes, we identified significant prognostic associations with overall survival, including SBT estimates of 5S rDNA (p=1.9x10-4, hazard ratio = 1.22) and TCR diversity (p=2.7x10-3, hazard ratio=1.77). Both novel survival associations replicated in 1,302 breast carcinoma and 1,651 colorectal cancer tumors. We anticipate that feature estimates derived by SBT will yield novel biomarker hypotheses and open research opportunities in existing and emerging clinical tumor sequencing cohorts.

genomics↗

Genetic determinants of chromatin reveal prostate cancer risk mediated by context-dependent gene regulation

Methods that link genetic variation to steady-state gene expression levels, such as expression quantitative trait loci (eQTLs), are widely used to functionally annotate trait-associated variants, but they are limited in identifying context-dependent effects on transcription. To address this challenge, we developed the cistrome-wide association study (CWAS), a framework for nominating variants that impact traits through their effects on chromatin state. CWAS associates the genetic determinants of cistromes (e.g., the genome-wide profiles of transcription factor binding sites or histone modifications) with traits using summary statistics from genome-wide association studies (GWAS). We performed CWASs of prostate cancer and androgen-related traits, using a reference panel of 307 prostate cistromes from 165 individuals. CWAS nominated susceptibility regulatory elements or androgen receptor (AR) binding sites at 52 out of 98 known prostate cancer GWAS loci and implicated an additional 17 novel loci. We functionally validated a subset of our results using CRISPRi and in vitro reporter assays. At 28 of the 52 risk loci, CWAS identified regulatory mechanisms that are not observable via eQTLs, implicating genes with complex or context-specific regulation that are overlooked by current approaches that relying on steady-state transcript measurements. CWAS genes include transcription factors that govern prostate development such as NKX3-1, HOXB13, GATA2, and KLF5. Moreover, CWAS boosts discovery power in modestly sized GWAS, identifying novel genetic associations mediated through AR binding for androgen-related phenotypes, including resistance to prostate cancer therapy. CWAS is a powerful and biologically interpretable paradigm for studying variants that influence traits by affecting context-dependent transcriptional regulation.

genetics↗